###### Significance of this study

What is already known about this subject?
=========================================

-   Saxagliptin, a dipeptidyl peptidase-4 inhibitor, is an oral antidiabetic drug used in combination with diet and exercise to control hyperglycemia in adults with type 2 diabetes mellitus.

-   Despite its widespread use in oral hypoglycemic therapy, few studies have evaluated the safety of saxagliptin in real-world settings.

What are the new findings?
==========================

-   Saxagliptin initiation was not associated with significantly increased incidence rates or risk of major adverse cardiovascular events, infection, acute kidney injury, acute liver failure, or severe hypersensitivity reactions.

How might these results change the focus of research or clinical practice?
==========================================================================

-   These data provide no evidence for concern about an increase in risk of these outcomes from saxagliptin in real-world settings.

Introduction {#s1}
============

Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is an oral antidiabetic drug (OAD) used in combination with diet and exercise to control hyperglycemia in adults with type 2 diabetes mellitus. This medication is approved for use as both monotherapy and combination therapy in the USA (approved July 2009) and as combination therapy in the European Union (approved October 2009).[@R1] Despite its widespread use in oral hypoglycemic therapy, few studies have evaluated the safety of saxagliptin in real-world settings. Since clinical trials are typically underpowered to detect uncommon, but potentially life-threatening, adverse reactions, postmarketing assessments are important to identify important medication-related toxicities in routine clinical practice.[@R3]

Prior to saxagliptin's approval in the USA and European Union, we designed an observational study within USA and UK practice settings to evaluate associations between saxagliptin and five outcomes of importance to patients with type 2 diabetes mellitus receiving OAD therapy, including major adverse cardiovascular events (MACE), acute liver failure (ALF), acute kidney injury (AKI), infections, and severe hypersensitivity reactions. After saxagliptin's approval, we prospectively collected data from 2009 to 2014 and compared the incidence rates and risk of each outcome between patients with type 2 diabetes mellitus who were new initiators of saxagliptin and those who were new initiators of OADs in classes other than DPP-4 inhibitors.

Research design and methods {#s2}
===========================

Data sources {#s2a}
------------

We conducted cohort studies within two UK medical record data sources (Clinical Practice Research Datalink (CPRD), The Health Improvement Network (THIN)) and two USA claims-based data sources (HealthCore Integrated Research Database (HIRD), Medicare).[@R4] The study protocol and variables evaluated within each data source were previously described.[@R5]

Within the UK, CPRD contains electronic healthcare records for \>15 million patients across 684 practices[@R6] and THIN contains medical records for \>11 million patients across 550 practices.[@R7] This study analyzed the first 52 months of saxagliptin availability within the UK (2009--2014), using the March 2014 version of CPRD and the 1401 version of THIN. CPRD and THIN collect demographics, medical diagnoses and surgical procedures (recorded using Read codes), outpatient laboratory results, general practitioner-issued prescriptions, hospital admission and discharge dates, and dates and causes of death from Office for National Statistics' death certificate data.[@R9] Since some practices contribute to both CPRD and THIN, we identified and excluded patients in THIN who were also present within CPRD to avoid double-counting these individuals within analyses.[@R11]

Within the USA, HIRD is a commercial health insurance database serving 23.2 million members.[@R12] We analyzed HIRD data over the first 53 months of saxagliptin availability in the USA (2009--2013). Medicare is a federal health insurance program available to Americans aged ≥65 years and those under 65 years with certain disabilities or chronic health conditions.[@R15] We analyzed Medicare data over the first 41 months of saxagliptin availability in the USA (2009--2012) only, due to the 18-month time-lag in Medicare data availability for research. Both HIRD and Medicare contain demographic information, inpatient and outpatient medical diagnoses (recorded using International Classification of Diseases, Ninth Revision codes), surgical procedures (recorded with Current Procedural Terminology codes), and dispensed medications (recorded by National Drug Codes). The National Death Index was used to determine date and cause of death in both USA databases. To prevent double-counting patients concurrently enrolled in both USA data sources, HIRD data were only included for patients 18--64 years of age and enrollees were censored at age 65 years.

This study was approved by the UK Independent Scientific Advisory Committees for CPRD (Protocol 10_149RMn) and THIN (Protocol 11--039V), Quorum Review Institutional Review Board for HIRD, and Institutional Review Boards of the University of Pennsylvania and Rutgers University. A data use agreement was obtained from the Centers for Medicare and Medicaid Services.

Study patients {#s2b}
--------------

Patients were eligible if they were (1) ≥18 years, (2) newly initiated saxagliptin or an OAD in a class other than DPP-4 inhibitors (with or without additional OADs), and (3) enrolled in their data source for ≥180 days prior to initiation of saxagliptin or comparator OAD. The exposed cohort consisted of initiators of saxagliptin, prescribed as a single agent or a fixed-dose combination with metformin. The unexposed cohort consisted of initiators of OADs in classes other than DPP-4 inhibitors. Our rationale for not including initiators of other DPP-4 inhibitors in the comparator group was to ensure that we did not miss potentially important associations related to the DPP-4 class. Patients were excluded from primary analyses (though included in a sensitivity analysis) if they received insulin or glucagon-like peptide-1 (GLP-1) receptor agonists, since at the time of protocol design thorough investigations regarding the use of these therapies with saxagliptin had not been performed.

Within each data source, we selected all eligible saxagliptin initiators and a random sample of up to 10 eligible initiators of non-DPP-4 inhibitor OADs matched on age (within 5-year age groups), sex, and geographic region (ie, census region for USA data sources; country for UK data sources) to each saxagliptin initiator, to ensure sufficient sample sizes for subanalyses.

The index date was the date of first prescription/claim for saxagliptin or comparator OAD. The 180 days prior to this date represented the baseline period. Follow-up continued until study outcome, drug discontinuation (ie, no further drug claim or prescription within 30 days after the last days' supply), non-saxagliptin DPP-4 inhibitor initiation, or end of study, whichever occurred first.

Main study outcomes {#s2c}
-------------------

The primary outcomes were (1) hospitalization with and/or death due to MACE, (2) hospitalization with ALF, (3) hospitalization for AKI, (4) hospitalization for infection, and (5) hospitalization for severe hypersensitivity reaction. We evaluated hospitalizations *for* AKI, infections, and hypersensitivity reactions because these conditions are frequently hospital-acquired. Evaluating hospitalizations *with* these conditions would leave open opportunities for diagnostic suspicion bias and include events that were not the main reason for hospitalization.[@R5]

End points were ascertained by diagnostic coding algorithms (see online [supplementary tables S1-S11](#SP1){ref-type="supplementary-material"}). MACE was defined by a hospital diagnosis of acute myocardial infarction (AMI), acute stroke, and/or death from cardiovascular causes (ie, AMI, acute stroke, congestive heart failure, dysrhythmia, sudden death, or coronary revascularization). Hospitalization with ALF was determined by inpatient diagnosis. Hospitalization for AKI was determined by inpatient AKI diagnosis plus at least one of the following within 7 days prior to admission: (1) emergency department AKI diagnosis, (2) outpatient AKI diagnosis, or (3) available serum creatinine result (within UK data) or claim for serum creatinine or serum chemistry panel including creatinine (within USA data). Hospitalization for infection was identified by inpatient infection diagnosis plus at least one of the following within 7 days prior to admission: (1) outpatient antimicrobial prescription/claim, (2) emergency department infection diagnosis, or (3) outpatient infection diagnosis. Hospitalization for severe hypersensitivity reaction was defined by (1) inpatient diagnosis for angioedema and/or generalized urticaria plus an emergency department or outpatient diagnosis of angioedema, urticaria, or rash within 7 days prior to admission; or (2) inpatient diagnosis for anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, or other severe skin reaction.
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Within each data source, we sampled patients who met each diagnostic coding algorithm, requested records from these patients from general practitioners (in the UK) and hospitals (in the USA) to enable confirmation of endpoints, had clinicians with expertise in each outcome review these records to adjudicate events using criteria we previously published,[@R5] and calculated the positive predictive value (PPV) of the algorithms for confirmed events (see online [supplementary table S12](#SP1){ref-type="supplementary-material"}). We sought algorithms with \>80% PPV to provide confidence that identified outcomes were true events. For any algorithm with \<80% PPV within a data source (AKI within CPRD and THIN; infection within CPRD; ALF and severe hypersensitivity reactions within all data sources), we classified patients as having an event if (1) the outcome was confirmed by adjudication or (2) the patient met the algorithm but had no records available to confirm the event.

Data collection {#s2d}
---------------

Baseline data included demographic information, medical diagnoses, surgical procedures, and medications commonly prescribed in type 2 diabetes ([table 1](#T1){ref-type="table"}). We ascertained prior OAD use within the 180 days preceding the index date. Patients were considered to have 'switched to' the index drug if they were prescribed/dispensed an OAD within the 90 days prior to their index date but this drug was not prescribed/dispensed in the 90 days after that date. Patients were considered to have 'added on' their index drug to their OAD therapy if they continued to receive the same OADs within the 90 days prior to and 90 days after their index date.

###### 

Demographic characteristics of patients with type 2 diabetes mellitus within the UK in the Clinical Practice Research Datalink (2009--2014) and The Health Improvement Network (2009--2014)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                             Clinical Practice Research Datalink   The Health Improvement Network                                            
  ------------------------------------------------------------------------------------------ ------------------------------------- -------------------------------- -------- --------------- --------------- --------
  Mean (SD) age, years†                                                                      54.65 (11.17)                         53.77 (11.88)                    0.0742   65.28 (13.11)   64.87 (13.10)   0.0313

  Male sex†                                                                                  2386 (57.1%)                          22 852 (56.5%)                   0.0124   517 (59.2%)     3234 (58.1%)    0.0223

  UK country^†^                                                                                                                                                                                              

    England                                                                                  2775 (66.4%)                          27 347 (67.6%)                   0.0252   496 (56.8%)     3507 (63.0%)    0.1271

    Northern Ireland                                                                         190 (4.5%)                            1843 (4.6%)                      0.0004   46 (5.3%)       246 (4.4%)      0.0395

    Scotland                                                                                 429 (10.3%)                           4235 (10.5%)                     0.0066   165 (18.9%)     1184 (21.3%)    0.0594

    Wales                                                                                    787 (18.8%)                           7055 (17.4%)                     0.0362   166 (19.0%)     627 (11.3%)     0.2174

  Other OAD initiated at index date                                                                                                                                                                          

    Alpha-glucosidase inhibitors: acarbose                                                   0 (0%)                                75 (0.2%)                        --       0 (0%)          15 (0.3%)       --

    Biguanide: metformin                                                                     0 (0%)                                27 151 (67.1%)                   --       0 (0%)          3155 (56.7%)    --

    Meglitinides                                                                             0 (0%)                                122 (0.3%)                       --       0 (0%)          16 (0.3%)       --

    Nateglinide                                                                              0 (0%)                                27 (0.1%)                        --       --              --              --

    Repaglinide                                                                              0 (0%)                                95 (0.2%)                        --       0 (0%)          16 (0.3%)       --

    Sodium-glucose cotransporter 2: dapagliflozin                                            0 (0%)                                50 (0.1%)                        --       0 (0%)          29 (0.5%)       --

    Sulfonylureas                                                                            0 (0%)                                10 869 (26.9%)                   --       0 (0%)          1907 (34.3%)    --

    Glibenclamide (glyburide in US data sources)                                             0 (0%)                                56 (0.1%)                        --       0 (0%)          6 (0.1%)        --

    Gliclazide                                                                               0 (0%)                                9823 (24.3%)                     --       0 (0%)          1696 (30.5%)    --

    Glimepiride                                                                              0 (0%)                                718 (1.8%)                       --       0 (0%)          145 (2.6%)      --

    Glipizide                                                                                0 (0%)                                218 (0.5%)                       --       0 (0%)          48 (0.9%)       --

    Tolbutamide                                                                              0 (0%)                                54 (0.1%)                        --       0 (0%)          12 (0.2%)       --

    Thiazolidinediones                                                                       0 (0%)                                2213 (5.5%)                      --       0 (0%)          442 (7.9%)      --

    Pioglitazone                                                                             0 (0%)                                2180 (5.4%)                      --       0 (0%)          437 (7.9%)      --

    Rosiglitazone                                                                            0 (0%)                                33 (0.1%)                        --       0 (0%)          5 (0.1%)        --

  On glucagon-like peptide-1 receptor agonist                                                102 (2.4%)                            821 (2.0%)                       0.0278   16 (1.8%)       110 (2.0%)      0.0106

  On insulin                                                                                 304 (7.3%)                            2813 (6.9%)                      0.0125   67 (7.7%)       365 (6.6%)      0.0434

  Hemoglobin A1c measurements                                                                                                                                                                                

    Mean (SD)                                                                                8.801 (1.59)                          8.646 (1.87)                     0.0844   8.907 (1.62)    8.605 (1.81)    0.1689

    Hemoglobin A1c\>8%                                                                       2518 (60.2%)                          16 166 (39.9%)                   0.4144   513 (58.8%)     2324 (41.8%)    0.3449

  Mean body mass index (SD)                                                                  32.23 (6.48)                          31.59 (6.73)                     0.0947   32.57 (6.47)    31.63 (6.42)    0.1468

    Missing values                                                                           29 (0.7%)                             1361 (3.4%)                      0.1902   6 (0.7%)        104 (1.9%)      0.1054

    Underweight (15--18.5 kg/m^2^)                                                           17 (0.4%)                             246 (0.6%)                       0.0283   1 (0.1%)        27 (0.5%)       0.0678

    Normal (18.5--24.9 kg/m^2^)                                                              343 (8.2%)                            4449 (11.0%)                     0.0947   75 (8.6%)       633 (11.4%)     0.0930

    Overweight (25.0--29.9 kg/m^2^)                                                          1171 (28.0%)                          11 811 (29.2%)                   0.0259   250 (28.6%)     1761 (31.6%)    0.0657

    Obese (30--60 kg/m^2^)                                                                   2621 (62.7%)                          22 613 (55.9%)                   0.1393   541 (62.0%)     3039 (54.6%)    0.1495

  Smoking                                                                                    2673 (63.9%)                          24 390 (60.3%)                   0.0759   529 (60.6%)     3450 (62.0%)    0.0290

  Severity of type 2 diabetes mellitus (prior 180 days)                                                                                                                                                      

    Cerebrovascular disease                                                                  27 (0.6%)                             262 (0.6%)                       0.0002   7 (0.8%)        39 (0.7%)       0.0117

   Coronary artery disease, congestive heart failure, ventricular tachycardia/fibrillation   82 (2.0%)                             561 (1.4%)                       0.0449   12 (1.4%)       80 (1.4%)       0.0054

    Diabetic coma                                                                            2 (0.0%)                              33 (0.1%)                        0.0133   0 (0%)          5 (0.1%)        --

    Nephropathy                                                                              16 (0.4%)                             72 (0.2%)                        0.0387   6 (0.7%)        14 (0.3%)       0.0638

    Neuropathy                                                                               39 (0.9%)                             249 (0.6%)                       0.0363   3 (0.3%)        37 (0.7%)       0.0454

    Peripheral vascular disease                                                              45 (1.1%)                             373 (0.9%)                       0.0156   7 (0.8%)        46 (0.8%)       0.0028

    Retinopathy                                                                              247 (5.9%)                            1331 (3.3%)                      0.1253   40 (4.6%)       209 (3.8%)      0.0413

    Unspecified additional diabetic complications                                            0 (0%)                                6 (0.0%)                         --       0 (0%)          3 (0.1%)        --

  Medical comorbidities                                                                                                                                                                                      

   Allergic rhinitis/hay fever                                                               398 (9.5%)                            4343 (10.7%)                     0.0401   59 (6.8%)       518 (9.3%)      0.0940

   Asthma                                                                                    711 (17.0%)                           6652 (16.4%)                     0.0153   137 (15.7%)     875 (15.7%)     0.0009

   Chronic obstructive pulmonary disease/bronchitis                                          562 (13.4%)                           3999 (9.9%)                      0.1112   84 (9.6%)       557 (10.0%)     0.0131

   Dermatological disorder                                                                                                                                                                                   

    Eczema                                                                                   733 (17.5%)                           6149 (15.2%)                     0.0633   108 (12.4%)     743 (13.4%)     0.0294

   Psoriasis/psoriatic arthritis                                                             268 (6.4%)                            2092 (5.2%)                      0.0532   40 (4.6%)       283 (5.1%)      0.0235

   Gastrointestinal disease                                                                                                                                                                                  

    Cirrhosis                                                                                16 (0.4%)                             138 (0.3%)                       0.0070   4 (0.5%)        18 (0.3%)       0.0216

    Gallbladder disease                                                                      255 (6.1%)                            2294 (5.7%)                      0.0184   61 (7.0%)       325 (5.8%)      0.0468

    Hemochromatosis                                                                          3 (0.1%)                              64 (0.2%)                        0.0255   1 (0.1%)        19 (0.3%)       0.0476

   Hyperlipidemia                                                                            636 (15.2%)                           4516 (11.2%)                     0.1201   119 (13.6%)     634 (11.4%)     0.0676

   Hypertension                                                                              2501 (59.8%)                          19 916 (49.2%)                   0.2145   562 (64.4%)     3194 (57.4%)    0.1432

   Infectious disease                                                                                                                                                                                        

    Hepatitis B virus infection                                                              9 (0.2%)                              65 (0.2%)                        0.0126   1 (0.1%)        8 (0.1%)        0.0081

    Hepatitis C virus infection                                                              2 (0.0%)                              49 (0.1%)                        0.0252   0 (0%)          5 (0.1%)        --

   Malignancy                                                                                                                                                                                                

    Hematological                                                                            36 (0.9%)                             380 (0.9%)                       0.0082   8 (0.9%)        54 (1.0%)       0.0056

    Solid organ                                                                              1020 (24.4%)                          9449 (23.3%)                     0.0247   188 (21.5%)     1316 (23.7%)    0.0506

   Obesity                                                                                   692 (16.6%)                           5951 (14.7%)                     0.0510   130 (14.9%)     726 (13.0%)     0.0532

   Rheumatoid arthritis                                                                      110 (2.6%)                            881 (2.2%)                       0.0297   9 (1.0%)        92 (1.7%)       0.0541

  Medications                                                                                                                                                                                                

   Acetaminophen/paracetamol                                                                 1363 (32.6%)                          11 320 (28.0%)                   0.1010   275 (31.5%)     1677 (30.1%)    0.0295

   Antiasthmatic agents                                                                      826 (19.8%)                           7326 (18.1%)                     0.0423   161 (18.4%)     1017 (18.3%)    0.0042

   Antibacterials                                                                            1566 (37.5%)                          13 997 (34.6%)                   0.0600   279 (32.0%)     1710 (30.7%)    0.0264

   Anticonvulsants                                                                           357 (8.5%)                            3287 (8.1%)                      0.0151   46 (5.3%)       292 (5.2%)      0.0009

   Antifungals                                                                               111 (2.7%)                            1066 (2.6%)                      0.0013   27 (3.1%)       210 (3.8%)      0.0374

   Antihistamines                                                                            306 (7.3%)                            2914 (7.2%)                      0.0046   72 (8.2%)       410 (7.4%)      0.0328

   Antihyperlipidemic agents                                                                 3362 (80.4%)                          22 358 (55.2%)                   0.5597   718 (82.2%)     3509 (63.1%)    0.4406

   Antihypertensive agents                                                                                                                                                                                   

    ACE inhibitors                                                                           1921 (45.9%)                          13 740 (33.9%)                   0.2469   405 (46.4%)     2151 (38.7%)    0.1569

    Angiotensin receptor blockers                                                            859 (20.5%)                           5111 (12.6%)                     0.2141   194 (22.2%)     829 (14.9%)     0.1892

    Beta blockers                                                                            1090 (26.1%)                          7928 (19.6%)                     0.1550   246 (28.2%)     1393 (25.0%)    0.0712

    Calcium channel blockers                                                                 1234 (29.5%)                          9403 (23.2%)                     0.1430   267 (30.6%)     1560 (28.0%)    0.0560

    Loop diuretics                                                                           656 (15.7%)                           4107 (10.1%)                     0.1659   163 (18.7%)     654 (11.8%)     0.1935

    Other antihypertensive agents                                                            440 (10.5%)                           2487 (6.1%)                      0.1590   90 (10.3%)      393 (7.1%)      0.1154

    Thiazide diuretics                                                                       808 (19.3%)                           6110 (15.1%)                     0.1123   220 (25.2%)     1180 (21.2%)    0.0947

   Antivirals                                                                                36 (0.9%)                             342 (0.8%)                       0.0018   11 (1.3%)       40 (0.7%)       0.0547

   Non-aspirin non-steroidal anti-inflammatory                                               474 (11.3%)                           5042 (12.5%)                     0.0346   106 (12.1%)     693 (12.5%)     0.0095

   Other antiplatelet/anticoagulant agents                                                                                                                                                                   

    Aspirin                                                                                  1590 (38.0%)                          10 625 (26.2%)                   0.2543   375 (43.0%)     1827 (32.8%)    0.2097

    Clopidogrel                                                                              229 (5.5%)                            1421 (3.5%)                      0.0950   42 (4.8%)       247 (4.4%)      0.0177

    Low-molecular-weight heparin                                                             10 (0.2%)                             148 (0.4%)                       0.0230   4 (0.5%)        22 (0.4%)       0.0096

    Warfarin                                                                                 241 (5.8%)                            1979 (4.9%)                      0.0390   66 (7.6%)       289 (5.2%)      0.0969

    Other medications                                                                                                                                                                                        

    Allopurinol                                                                              183 (4.4%)                            1396 (3.4%)                      0.0479   54 (6.2%)       204 (3.7%)      0.1166

    Antiarrhythmics                                                                          125 (3.0%)                            1021 (2.5%)                      0.0286   30 (3.4%)       181 (3.3%)      0.0102

   Immune modulators/\                                                                       56 (1.3%)                             488 (1.2%)                       0.0119   11 (1.3%)       71 (1.3%)       0.0014
   immunosuppressants                                                                                                                                                                                        

    Nitroglycerin                                                                            251 (6.0%)                            1788 (4.4%)                      0.0714   44 (5.0%)       284 (5.1%)      0.0029

    Urinary antispasmodics                                                                   217 (5.2%)                            1357 (3.4%)                      0.0910   42 (4.8%)       199 (3.6%)      0.0616

   Psychotropic agents                                                                                                                                                                                       

    Antidepressants                                                                          912 (21.8%)                           8094 (20.0%)                     0.0447   179 (20.5%)     1134 (20.4%)    0.0030

    Antipsychotics                                                                           186 (4.4%)                            1795 (4.4%)                      0.0007   47 (5.4%)       269 (4.8%)      0.0249

  Prior OAD therapy^‡^                                                                       3905 (93.4%)                          12 855 (31.8%)                   1.6523   814 (93.2%)     2228 (40.0%)    1.3665

    Alpha-glucosidase inhibitors: acarbose                                                   13 (0.3%)                             47 (0.1%)                        0.0422   3 (0.3%)        10 (0.2%)       0.0320

   Biguanide: metformin                                                                      3384 (80.9%)                          9857 (74.0%)                     0.1677   681 (78.0%)     1800 (74.7%)    0.0774

   Meglitinides                                                                              46 (1.1%)                             97 (0.2%)                        0.1056   7 (0.8%)        11 (0.2%)       0.0858

    Nateglinide                                                                              7 (0.2%)                              16 (0.0%)                        0.0398   --              --              --

    Repaglinide                                                                              40 (1.0%)                             81 (0.2%)                        0.0998   6 (0.7%)        7 (0.1%)        0.0882

    Sodium-glucose cotransporter 2: dapagliflozin                                            1 (0.0%)                              1 (0.0%)                         0.0187   0 (0%)          2 (0.0%)        --

    Sulfonylureas                                                                            1984 (47.5%)                          4042 (10.0%)                     0.9097   428 (49.0%)     661 (11.9%)     0.8822

    Glibenclamide                                                                            14 (0.3%)                             154 (0.4%)                       0.0077   6 (0.7%)        38 (0.7%)       0.0004

    Gliclazide                                                                               1689 (40.4%)                          3176 (10.4%)                     0.7354   362 (41.5%)     499 (12.9%)     0.6779

    Glimepiride                                                                              212 (5.1%)                            464 (1.2%)                       0.2260   29 (3.3%)       79 (1.5%)       0.1223

    Glipizide                                                                                52 (1.2%)                             214 (0.5%)                       0.0760   27 (3.1%)       35 (0.6%)       0.1825

    Tolbutamide                                                                              27 (0.6%)                             51 (0.1%)                        0.0839   6 (0.7%)        14 (0.3%)       0.0637

    Thiazolidinediones                                                                       614 (14.7%)                           1527 (3.8%)                      0.3839   145 (16.6%)     254 (4.6%)      0.3992

    Pioglitazone                                                                             563 (13.5%)                           1107 (2.9%)                      0.3933   135 (15.5%)     167 (3.3%)      0.4286

    Rosiglitazone                                                                            54 (1.3%)                             427 (1.1%)                       0.0219   12 (1.4%)       88 (1.6%)       0.0173
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Characteristics are presented as percentages unless otherwise indicated.

Matching criteria for which a random sample (without replacement) of up to 10 new initiators of non-DPP-4 inhibitor OADs were selected for each saxagliptin initiator.

Defined as use of an OAD within the 180 days prior to the initiation of the index drug. Denominator adjusted to exclude the index drug.

Standardized difference was calculated as the difference in mean (or proportion for binary variables) divided by the SD (pooled SD for continuous variables).

DPP-4, dipeptidyl peptidase-4; OAD, oral antidiabetic drug.

Within the UK data sources, we collected the most recent hemoglobin A1c result prior to the index date, smoking status, and obesity (body mass index \>30 kg/m^2^). Within the USA data sources, we collected the number of claims for hemoglobin A1c tests recorded in the baseline period since laboratory results were not available for all enrollees within these data.

Statistical analysis {#s2e}
--------------------

Within each data source, we compared characteristics between saxagliptin and comparator OAD initiators. Patients who had a study end point during the baseline period were excluded from analyses of that outcome. Unadjusted incidence rates of outcomes were calculated by cohort in each data source.

Because of the many potential confounders relative to the number of outcomes, we used propensity scores to control for confounding.[@R16] Propensity scores were developed within each data source using logistic regression, incorporating measured potential predictors of saxagliptin as independent variables and saxagliptin exposure as the dependent variable. We excluded patients from the saxagliptin cohort whose propensity score exceeded the maximum or minimum values in the comparator OAD cohort (trimmed the tails). All variables in [tables 1 and 2](#T1 T2){ref-type="table"} were included in propensity score models.

###### 

Demographic characteristics of patients with type 2 diabetes mellitus within the USA in Medicare (2009--2012) and the HealthCore Integrated Research Database (2009--2013)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                              Medicare         HealthCore Integrated Reseach Database                                            
  ------------------------------------------------------------------------------------------- ---------------- ---------------------------------------- -------- -------------- ---------------- --------
  Mean (SD) age, years^†^                                                                     70.46 (10.96)    69.86 (10.99)                            0.0546   52.84 (8.39)   52.67 (8.48)     0.0196

  Male sex^†^                                                                                 39 916 (43.1%)   322 205 (43.5%)                          0.0082   6303 (59.9%)   59 665 (59.5%)   0.0091

  US census region^†^                                                                                                                                                                            

    East North Central                                                                        11 453 (12.4%)   96 833 (13.1%)                           0.0213   2245 (21.3%)   21 668 (21.6%)   0.0062

    East South Central                                                                        8921 (9.6%)      71 154 (9.6%)                            0.0009   1088 (10.3%)   10 425 (10.4%)   0.0016

    Middle Atlantic                                                                           15 272 (16.5%)   114 684 (15.5%)                          0.0274   897 (8.5%)     8396 (8.4%)      0.0057

    Mountain                                                                                  2952 (3.2%)      25 016 (3.4%)                            0.0107   305 (2.9%)     2944 (2.9%)      0.0021

    New England                                                                               2929 (3.2%)      22 293 (3.0%)                            0.0088   600 (5.7%)     5863 (5.8%)      0.0060

    Pacific                                                                                   12 134 (13.1%)   97 652 (13.2%)                           0.0025   1463 (13.9%)   14 209 (14.2%)   0.0073

    South Atlantic                                                                            22 116 (23.9%)   177 647 (24.0%)                          0.0025   3135 (29.8%)   29 474 (29.4%)   0.0093

    West North Central                                                                        4896 (5.3%)      37 258 (5.0%)                            0.0116   548 (5.2%)     5339 (5.3%)      0.0050

    West South Central                                                                        11 900 (12.9%)   97 790 (13.2%)                           0.0105   240 (2.3%)     2025 (2.0%)      0.0181

  Other OAD initiated at index date                                                                                                                                                              

    Alpha-glucosidase inhibitors                                                              0 (0%)           4334 (0.6%)                              --       0 (0%)         343 (0.3%)       --

    Acarbose                                                                                  0 (0%)           4050 (0.5%)                              --       0 (0%)         313 (0.3%)       --

    Miglitol                                                                                  0 (0%)           284 (0.0%)                               --       0 (0%)         30 (0.0%)        --

    Biguanide: metformin                                                                      0 (0%)           388 385 (52.5%)                          --       0 (0%)         70 944 (70.7%)   --

    Meglitinides                                                                              0 (0%)           17 007 (2.3%)                            --       0 (0%)         802 (0.8%)       --

    Nateglinide                                                                               0 (0%)           7652 (1.0%)                              --       0 (0%)         374 (0.4%)       --

    Repaglinide                                                                               0 (0%)           9355 (1.3%)                              --       0 (0%)         428 (0.4%)       --

    Sodium-glucose cotransporter 2: canagliflozin                                             0 (0%)           0 (0%)                                   --       0 (0%)         313 (0.3%)       --

    Sulfonylureas                                                                             0 (0%)           258 866 (35.0%)                          --       0 (0%)         21 196 (21.1%)   --

    Chlorpropamide                                                                            0 (0%)           141 (0.0%)                               --       0 (0%)         6 (0.0%)         --

    Glimepiride                                                                               0 (0%)           85 584 (11.6%)                           --       0 (0%)         7860 (7.8%)      --

    Glipizide                                                                                 0 (0%)           110 556 (14.9%)                          --       0 (0%)         8098 (8.1%)      --

    Glyburide (glibenclamide in UK data sources)                                              0 (0%)           61 794 (8.3%)                            --       0 (0%)         5182 (5.2%)      --

    Tolazamide                                                                                0 (0%)           725 (0.1%)                               --       0 (0%)         48 (0.0%)        --

    Tolbutamide                                                                               0 (0%)           66 (0.0%)                                --       0 (0%)         2 (0.0%)         --

    Thiazolidinediones                                                                        0 (0%)           71 254 (9.6%)                            --       0 (0%)         6620 (6.6%)      --

    Pioglitazone                                                                              0 (0%)           67 603 (9.1%)                            --       0 (0%)         6295 (6.3%)      --

    Rosiglitazone                                                                             0 (0%)           3651 (0.5%)                              --       0 (0%)         325 (0.3%)       --

  On glucagon-like peptide-1 receptor agonist                                                 0 (0%)           0 (0%)                                   --       0 (0%)         0 (0%)           --

  On insulin                                                                                  14 716 (15.9%)   115 148 (15.6%)                          0.0094   1073 (10.2%)   8469 (8.4%)      0.0605

  Mean (SD) number of hemoglobin A1c measures                                                 1.303 (0.88)     0.910 (0.86)                             0.4572   1.148 (0.79)   0.771 (0.74)     0.5066

  Severity of type 2 diabetes mellitus (prior 180 days)                                                                                                                                          

    Cerebrovascular disease                                                                   9607 (10.4%)     77 376 (10.5%)                           0.0024   242 (2.3%)     2288 (2.3%)      0.0013

    Coronary artery disease, congestive heart failure, ventricular tachycardia/fibrillation   36 836 (39.8%)   279 939 (37.8%)                          0.0406   1203 (11.4%)   10 791 (10.8%)   0.0217

    Metabolic (ketoacidosis, hyperosmolar coma)                                               1199 (1.3%)      9220 (1.2%)                              0.0044   80 (0.8%)      724 (0.7%)       0.0045

    Nephropathy                                                                               18 387 (19.9%)   118 385 (16.0%)                          0.1010   544 (5.2%)     3549 (3.5%)      0.0801

    Neuropathy                                                                                20 973 (22.7%)   138 634 (18.7%)                          0.0971   884 (8.4%)     6599 (6.6%)      0.0694

    Peripheral vascular disease                                                               16 822 (18.2%)   122 379 (16.5%)                          0.0433   410 (3.9%)     3266 (3.3%)      0.0346

    Retinopathy                                                                               12 102 (13.1%)   77 603 (10.5%)                           0.0804   539 (5.1%)     3665 (3.7%)      0.0718

    Unspecified additional diabetic complications                                             7123 (7.7%)      51 544 (7.0%)                            0.0281   407 (3.9%)     2714 (2.7%)      0.0653

  Medical comorbidities                                                                                                                                                                          

   Allergic rhinitis/hay fever                                                                6430 (6.9%)      41 153 (5.6%)                            0.0573   542 (5.2%)     4623 (4.6%)      0.0253

   Asthma                                                                                     7001 (7.6%)      57 683 (7.8%)                            0.0086   407 (3.9%)     4300 (4.3%)      0.0211

   Chronic obstructive pulmonary disease/bronchitis                                           11 171 (12.1%)   97 901 (13.2%)                           0.0348   286 (2.7%)     2949 (2.9%)      0.0133

   Dermatological disorders                                                                                                                                                                      

    Eczema                                                                                    3240 (3.5%)      22 611 (3.1%)                            0.0250   225 (2.1%)     1916 (1.9%)      0.0163

    Psoriasis/psoriatic arthritis                                                             877 (0.9%)       6808 (0.9%)                              0.0029   96 (0.9%)      887 (0.9%)       0.0030

   Gastrointestinal disease                                                                                                                                                                      

    Cirrhosis                                                                                 686 (0.7%)       6014 (0.8%)                              0.0081   32 (0.3%)      360 (0.4%)       0.0095

    Gallbladder disease                                                                       1953 (2.1%)      16 763 (2.3%)                            0.0106   111 (1.1%)     1137 (1.1%)      0.0075

    Hemochromatosis                                                                           200 (0.2%)       1422 (0.2%)                              0.0053   17 (0.2%)      164 (0.2%)       0.0005

   Hyperlipidemia                                                                             71 221 (76.9%)   492 578 (66.5%)                          0.2324   6550 (62.3%)   48 349 (48.2%)   0.2859

   Hypertension                                                                               78 403 (84.7%)   577 668 (78.0%)                          0.1717   6397 (60.8%)   50 751 (50.6%)   0.2069

   Infections                                                                                                                                                                                    

    Hepatitis B virus infection                                                               258 (0.3%)       1646 (0.2%)                              0.0113   20 (0.2%)      134 (0.1%)       0.0141

    Hepatitis C virus infection                                                               725 (0.8%)       6826 (0.9%)                              0.0151   56 (0.5%)      482 (0.5%)       0.0073

    HIV                                                                                       220 (0.2%)       2722 (0.4%)                              0.0237   8 (0.1%)       172 (0.2%)       0.0271

   Malignancy                                                                                                                                                                                    

    Hematological                                                                             1157 (1.2%)      10 146 (1.4%)                            0.0106   63 (0.6%)      574 (0.6%)       0.0035

    Solid organ                                                                               7837 (8.5%)      63 813 (8.6%)                            0.0055   339 (3.2%)     3174 (3.2%)      0.0034

   Obesity                                                                                    10 711 (11.6%)   84 346 (11.4%)                           0.0055   1006 (9.6%)    9899 (9.9%)      0.0102

    Rheumatoid arthritis                                                                      2538 (2.7%)      18 429 (2.5%)                            0.0158   90 (0.9%)      843 (0.8%)       0.0017

  Medications                                                                                                                                                                                    

   Acetaminophen/\                                                                            24 456 (26.4%)   1 94 424 (26.3%)                         0.0035   2091 (19.9%)   19 897 (19.8%)   0.0011
   paracetamol                                                                                                                                                                                   

   Antiasthmatic agents                                                                       12 734 (13.8%)   92 459 (12.5%)                           0.0375   836 (7.9%)     7720 (7.7%)      0.0094

   Antibacterials                                                                             35 628 (38.5%)   257 225 (34.7%)                          0.0777   3286 (31.2%)   29 277 (29.2%)   0.0448

   Anticonvulsants                                                                            4707 (5.1%)      41 871 (5.7%)                            0.0253   768 (7.3%)     7682 (7.7%)      0.0135

   Antifungals                                                                                9132 (9.9%)      60 580 (8.2%)                            0.0587   735 (7.0%)     5858 (5.8%)      0.0469

   Antihistamines                                                                             9142 (9.9%)      61 223 (8.3%)                            0.0559   645 (6.1%)     5406 (5.4%)      0.0319

   Antihyperlipidemic agents                                                                  59 126 (63.9%)   375 758 (50.8%)                          0.2674   5233 (49.7%)   35 934 (35.8%)   0.2843

    Antihypertensive agents                                                                                                                                                                      

    ACE inhibitors                                                                            38 296 (41.4%)   278 503 (37.6%)                          0.0767   3736 (35.5%)   27 518 (27.4%)   0.1748

    Angiotensin receptor blockers                                                             25 262 (27.3%)   133 659 (18.1%)                          0.2219   2034 (19.3%)   13 433 (13.4%)   0.1613

    Beta blockers                                                                             38 938 (42.1%)   268 421 (36.3%)                          0.1191   2219 (21.1%)   18 338 (18.3%)   0.0709

    Calcium channel blockers                                                                  28 176 (30.4%)   194 430 (26.3%)                          0.0927   1670 (15.9%)   13 557 (13.5%)   0.0668

    Loop diuretics                                                                            19 448 (21.0%)   131 150 (17.7%)                          0.0834   524 (5.0%)     4726 (4.7%)      0.0126

    Other antihypertensive agents                                                             10 023 (10.8%)   65 686 (8.9%)                            0.0656   474 (4.5%)     3840 (3.8%)      0.0340

    Thiazide diuretics                                                                        18 813 (20.3%)   113 540 (15.3%)                          0.1305   1846 (17.5%)   14 470 (14.4%)   0.0854

   Antivirals                                                                                 2005 (2.2%)      15 077 (2.0%)                            0.0090   197 (1.9%)     2468 (2.5%)      0.0403

   Non-aspirin non-steroidal anti-inflammatory                                                15 506 (16.7%)   109 437 (14.8%)                          0.0540   1488 (14.1%)   13 098 (13.1%)   0.0318

   Other antiplatelet/\                                                                                                                                                                          
   anticoagulant agents                                                                                                                                                                          

    Aspirin                                                                                   644 (0.7%)       4504 (0.6%)                              0.0108   16 (0.2%)      142 (0.1%)       0.0028

    Clopidogrel                                                                               11 150 (12.0%)   69 439 (9.4%)                            0.0862   363 (3.5%)     3035 (3.0%)      0.0240

    Low-molecular-weight heparin                                                              372 (0.4%)       3889 (0.5%)                              0.0182   32 (0.3%)      288 (0.3%)       0.0032

    Warfarin                                                                                  6459 (7.0%)      51 316 (6.9%)                            0.0018   203 (1.9%)     1652 (1.6%)      0.0214

   Other medications                                                                                                                                                                             

    Allopurinol                                                                               4924 (5.3%)      31 821 (4.3%)                            0.0477   270 (2.6%)     2408 (2.4%)      0.0107

    Antiarrhythmics                                                                           11 895 (12.8%)   88 324 (11.9%)                           0.0279   489 (4.6%)     4407 (4.4%)      0.0123

    Immune modulators/\                                                                       3986 (4.3%)      29 604 (4.0%)                            0.0154   223 (2.1%)     2400 (2.4%)      0.0183
   immunosuppressants                                                                                                                                                                            

    Nitroglycerin                                                                             3995 (4.3%)      27 908 (3.8%)                            0.0277   137 (1.3%)     1241 (1.2%)      0.0058

    Urinary antispasmodics                                                                    4692 (5.1%)      32 809 (4.4%)                            0.0299   112 (1.1%)     1185 (1.2%)      0.0110

   Psychotropic agents                                                                                                                                                                           

    Antidepressants                                                                           24 264 (26.2%)   186 970 (25.3%)                          0.0218   1992 (18.9%)   18 828 (18.8%)   0.0043

    Antipsychotics                                                                            6305 (6.8%)      54 109 (7.3%)                            0.0195   222 (2.1%)     2197 (2.2%)      0.0055

  Prior OAD therapy^‡^                                                                        68 160 (73.6%)   273 289 (36.9%)                          0.7944   6957 (66.1%)   21 797 (21.7%)   1.0004

    Alpha-glucosidase inhibitors                                                              715 (0.8%)       1988 (0.3%)                              0.0701   38 (0.4%)      118 (0.1%)       0.0499

    Acarbose                                                                                  636 (0.7%)       1730 (0.2%)                              0.0668   35 (0.3%)      108 (0.1%)       0.0479

    Miglitol                                                                                  84 (0.1%)        260 (0.0%)                               0.0222   4 (0.0%)       10 (0.0%)        0.0181

    Biguanide: metformin                                                                      46 101 (49.8%)   1 40 212 (39.8%)                         0.2013   5500 (52.3%)   12 578 (42.8%)   0.1909

    Meglitinides                                                                              2430 (2.6%)      7708 (1.0%)                              0.1183   140 (1.3%)     375 (0.4%)       0.1042

    Nateglinide                                                                               1235 (1.3%)      3467 (0.5%)                              0.0911   75 (0.7%)      182 (0.2%)       0.0796

    Repaglinide                                                                               1231 (1.3%)      4286 (0.6%)                              0.0764   67 (0.6%)      193 (0.2%)       0.0691

    Sodium-glucose cotransporter 2: canagliflozin                                             --               --                                       --       5 (0.0%)       10 (0.0%)        0.0221

    Sulfonylureas                                                                             36 848 (39.8%)   127 737 (17.3%)                          0.5157   2874 (27.3%)   8168 (8.1%)      0.5187

    Chlorpropamide                                                                            21 (0.0%)        221 (0.0%)                               0.0044   1 (0.0%)       3 (0.0%)         0.0082

    Glimepiride                                                                               14 315 (15.5%)   35 805 (5.5%)                            0.3309   1262 (12.0%)   2759 (3.0%)      0.3475

    Glipizide                                                                                 15 451 (16.7%)   56 241 (8.9%)                            0.2338   1139 (10.8%)   3591 (3.9%)      0.2679

    Glyburide                                                                                 8116 (8.8%)      36 892 (5.4%)                            0.1299   526 (5.0%)     1863 (2.0%)      0.1666

    Tolazamide                                                                                3 (0.0%)         72 (0.0%)                                0.0081   0 (0%)         10 (0.0%)        --

    Tolbutamide                                                                               12 (0.0%)        54 (0.0%)                                0.0056   1 (0.0%)       1 (0.0%)         0.0117

    Thiazolidinediones                                                                        18 258 (19.7%)   54 840 (7.4%)                            0.3656   1376 (13.1%)   4832 (4.8%)      0.2926

    Pioglitazone                                                                              16 698 (18.0%)   45 435 (6.8%)                            0.3475   1260 (12.0%)   4071 (4.3%)      0.2822

    Rosiglitazone                                                                             1762 (1.9%)      9661 (1.3%)                              0.0471   123 (1.2%)     785 (0.8%)       0.0391
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Characteristics are presented as percentages unless otherwise indicated.

Matching criteria for which a random sample (without replacement) of up to 10 new initiators of non-DPP-4 inhibitor OADs were selected for each saxagliptin initiator.

Defined as use of an OAD within the 180 days prior to the initiation of the index drug. Denominator adjusted to exclude the index drug.

Standardized difference was calculated as the difference in mean (or proportion for binary variables) divided by the SD (pooled SD for continuous variables).

DPP-4, dipeptidyl peptidase-4; OAD, oral antidiabetic drug.

Cox regression was used to determine HRs with 95% CIs of outcomes in saxagliptin versus other OAD initiators, adjusting for propensity score, prior OAD therapy, quarter of observation, and geographic region. We adjusted for, rather than stratified or matched on, propensity score within multivariable models because (1) there were too few events within some propensity score strata to perform stratification and (2) unmatched saxagliptin initiators would have been excluded, reducing power to detect associations.

Meta-analyses of each outcome across data sources were performed as data permitted. The presence of heterogeneity in HRs across data sources was evaluated using the I^2^ statistic.[@R17]

We performed sensitivity analyses to (1) evaluate outcomes when the cohorts were expanded to include patients prescribed/dispensed insulin or GLP-1 agonists and (2) examine the effect of unmeasured confounders on HRs of each outcome associated with saxagliptin use.[@R18] Details appear in online [supplementary methods](#SP1){ref-type="supplementary-material"}. Data were analyzed using SAS V.9.4.

Results {#s3}
=======

Patient characteristics {#s3a}
-----------------------

We identified 110 740 eligible saxagliptin initiators and 913 384 eligible other OAD initiators (see online [supplementary figure S1](#SP1){ref-type="supplementary-material"}a-d). These patients' characteristics are presented in [tables 1](#T1){ref-type="table"} (UK) and 2 (USA). Across the four data sources, the average follow-up ranged from 6.8 to 8.1 months among saxagliptin initiators and 5.6 to 7.0 months among other OAD initiators. Saxagliptin initiators more commonly had hypertension and were more frequently prescribed/dispensed antihyperlipidemics, antihypertensives, and prior OAD therapy (metformin, sulfonylureas, and/or thiazolidinediones). Metformin initiators constituted the majority of the comparator OAD cohort.

The numbers of confirmed events following medical record review and PPVs of diagnostic coding algorithms varied by end point and data source (see online [supplementary table S12](#SP1){ref-type="supplementary-material"}).

Risk of MACE {#s3b}
------------

There was no increased risk of MACE associated with saxagliptin initiation within any of the four data sources. Within Medicare, the incidence rate and risk of MACE was lower for saxagliptin than for other OAD initiators (HR 0.92, 95% CI, 0.86 to 0.98; [table 3](#T3){ref-type="table"}). Meta-analysis of results across the four data sources demonstrated a lower risk of MACE associated with saxagliptin initiation (HR 0.91, 95% CI 0.85 to 0.97; [figure 1A](#F1){ref-type="fig"}).

![Meta-analyses of HRs (with 95% CIs) of hospitalization with and/or death due to a major adverse cardiovascular event (A), hospitalization for acute kidney injury (B), and hospitalization for infection (C) across the data sources. CPRD, Clinical Practice Research Datalink; HIRD, HealthCore Integrated Research Database; THIN, The Health Improvement Network.](bmjdrc-2017-000400f01){#F1}

###### 

Incidence rates and HRs of outcomes, by data source

                                                         Saxagliptin initiators   Other OAD initiators                                                                                     
  ------------------------------------------------------ ------------------------ ---------------------- ------ --------------------- --------- ----------- -------- --------------------- --------------------------------------------------
   Major cardiovascular event                                                                                                                                                              
   Medicare                                              70 271                   39 300.8               1030   26.2 (24.6 to 27.9)   562 159   308 101.7   8945     29.0 (28.4 to 29.6)   0.92 (0.86 to 0.98)
   HIRD                                                  9219                     5988.1                 45     7.5 (5.5 to 10.1)     89 538    41 694.0    362      8.7 (7.8 to 9.6)      0.86 (0.62 to 1.20)
   CPRD                                                  3769                     2551.4                 13     5.1 (2.7 to 8.7)      35 916    20 245.3    145      7.2 (6.0 to 8.4)      0.63 (0.35 to 1.16)
   THIN (excluding CPRD)                                 785                      524.3                  5      9.5 (3.1 to 22.3)     4873      2850.8      21       7.4 (4.6 to 11.3)     0.99 (0.34 to 2.87)
  Acute liver failure                                                                                                                                                                      
   Medicare^[†](#tblfn12){ref-type="fn"}^                72 831                   41 011.4               28     0.7 (0.5 to 1.0)      72 831    37 260.1    40       1.1 (0.8 to 1.5)      0.72 (0.42 to 1.25)
   HIRD^[†](#tblfn12){ref-type="fn"}^                    9265                     6059.8                 2      0.3 (0.04 to 1.2)     90 174    42 230.7    6        0.1 (0.05 to 0.3)     2.97 (0.49 to 18.11)[‡](#tblfn13){ref-type="fn"}
   CPRD^[†](#tblfn12){ref-type="fn"}^                    3794                     2581.4                 0      0.0 (0.0 to 1.2)      36 196    20 549.8    0        0.0 (0.0 to 0.1)      --
   THIN (excluding CPRD)^[†](#tblfn12){ref-type="fn"}^   791                      531.0                  0      0.0 (0.0 to 5.6)      4913      2879.5      0        0.0 (0.0 to 1.0)      --
  Acute kidney injury                                                                                                                                                                      
   Medicare                                              61 888                   34 597.7               334    9.7 (8.6 to 10.7)     519 259   289 326.5   2708     9.4 (9.0 to 9.7)      0.99 (0.88 to 1.11)
   HIRD                                                  8894                     5819.5                 4      0.7 (0.2 to 1.8)      87 770    40 979.4    26       0.6 (0.4 to 0.9)      0.88 (0.29 to 2.74)
   CPRD^[†](#tblfn12){ref-type="fn"}^                    2972                     1947.4                 0      0.0 (0.0 to 1.5)      32 798    18 369.1    7        0.4 (0.2 to 0.8)      --
   THIN (excluding CPRD)^[†](#tblfn12){ref-type="fn"}^   602                      412.8                  0      0.0 (0.0 to 7.3)      4327      2522.3      2        0.8 (0.10 to 2.9)     --
  Infection                                                                                                                                                                                
   Medicare                                              74 263                   41 012.6               2280   55.6 (53.3 to 57.9)   577 572   314 496.9   17 840   56.7 (55.9 to 57.6)   0.97 (0.92 to 1.01)
   HIRD                                                  9300                     6047.8                 84     13.9 (11.1 to 17.2)   89 485    41 773.4    552      13.2 (12.1 to 14.4)   1.07 (0.83 to 1.37)
   CPRD^[†](#tblfn12){ref-type="fn"}^                    3714                     2456.9                 74     30.1 (23.7 to 37.8)   35 417    19 687.2    661      33.6 (31.1 to 36.2)   0.81 (0.63 to 1.06)
   THIN (excluding CPRD)                                 780                      508.9                  2      3.9 (0.5 to 14.2)     4834      2785.5      18       6.5 (3.8 to 10.2)     0.64 (0.13 to 3.16)
  Hypersensitivity                                                                                                                                                                         
   Medicare^[†](#tblfn12){ref-type="fn"}^                77 857                   43 764.4               75     1.7 (1.3 to 2.1)      624 074   342 886.0   702      2.0 (1.9 to 2.2)      0.80 (0.62 to 1.02)
   HIRD^[†](#tblfn12){ref-type="fn"}^                    9439                     6162.2                 4      0.6 (0.2 to 1.7)      91 814    42 887.8    72       1.7 (1.3 to 2.1)      0.48 (0.17 to 1.38)
   CPRD^[†](#tblfn12){ref-type="fn"}^                    3795                     2581.5                 2      0.8 (0.09 to 2.8)     36 245    20 558.8    13       0.6 (0.3 to 1.1)      1.80 (0.31 to 10.28)[‡](#tblfn13){ref-type="fn"}
   THIN (excluding CPRD)^[†](#tblfn12){ref-type="fn"}^   792                      531.6                  0      0.0 (0.0 to 5.6)      4921      2884.2      0        0.0 (0.0 to 1.0)      --

\*Adjusted for prior OAD therapy, quarter of observation, and geographic region unless otherwise noted.

†A validated algorithm was unable to be determined, so, conservatively, we included all electronically identified outcomes that were either confirmed by medical record review or had unobtained charts as events.

‡Since there were not enough events to run the fully adjusted model, the propensity score-adjusted HR is presented.

CPRD, Clinical Practice Research Datalink; HIRD, HealthCore Integrated Research Database; OAD, oral antidiabetic drug; THIN, The Health Improvement Network.

Risk of ALF {#s3c}
-----------

There was no increased risk of ALF associated with saxagliptin initiation within each data source ([table 3](#T3){ref-type="table"}). Across the data sources, no saxagliptin initiators and only one comparator OAD initiator (within Medicare) developed ALF, and medical record review determined this was not drug-related. There were too few ALF events to permit meta-analysis.

Risk of AKI {#s3d}
-----------

There was no association between saxagliptin initiation and hospitalization for AKI across the data sources ([table 3](#T3){ref-type="table"}). Meta-analysis across the USA data sources demonstrated no increased risk of AKI with saxagliptin (HR 0.99, 95% CI, 0.88 to 1.11; [figure 1B](#F1){ref-type="fig"}). The UK data sources were not included in the meta-analysis due to few events.

Risk of infection {#s3e}
-----------------

Across the data sources, there was no association between saxagliptin initiation and hospitalization for infection ([table 3](#T3){ref-type="table"}). Meta-analysis of results within THIN, Medicare, and HIRD showed no increased risk of this outcome (HR 0.97, 95% CI 0.93 to 1.02; [figure 1C](#F1){ref-type="fig"}). Data from CPRD were not included because the diagnostic coding algorithm had \<80% PPV.

Risk of severe hypersensitivity reactions {#s3f}
-----------------------------------------

There were no significant differences in incidence rates or risk of hospitalization for severe hypersensitivity reactions between saxagliptin and other OAD initiators within each data source ([table 3](#T3){ref-type="table"}). Across the data sources, only one saxagliptin initiator (within Medicare) had an event confirmed by medical record review. Due to the low number of events, we were unable to perform a meta-analysis.

Sensitivity analyses {#s3g}
--------------------

When the cohorts were expanded to include patients who were prescribed/dispensed insulin and/or a GLP-1 agonist, there was no increased risk of any outcome within each data source (see online [supplementary table S13](#SP1){ref-type="supplementary-material"}). Across all data sources, sensitivity analyses to determine the potential impact of unmeasured confounders determined that the HRs for each outcome were not sensitive to unmeasured confounding (see online[supplementary table S14](#SP1){ref-type="supplementary-material"}).

Conclusions {#s4}
===========

This very large family of cohort studies of two UK healthcare record data sources and two USA claims-based data sources (analyzed individually and combined via meta-analyses) found no increases in incidence rates or risk of hospitalization with or death due to MACE, hospitalization with ALF, or hospitalization for AKI, infection, or severe hypersensitivity reaction among new initiators of saxagliptin compared with new initiators of OADs in non-DPP-4 inhibitor classes.

Consistent with previously published studies,[@R19] we found no evidence of increased risk of MACE associated with saxagliptin initiation. A meta-analysis of 53 clinical trials for DPP-4 inhibitors found a reduced risk of MACE among patients prescribed DPP-4 inhibitors compared with those prescribed placebo or comparator therapies.[@R19] Similarly, the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus--Thrombolysis in Myocardial Infarction 53 trial found that saxagliptin use was not associated with a higher risk of AMI, ischemic stroke, or cardiovascular death.[@R23] Our findings provide further evidence that saxagliptin is not associated with an increased risk of MACE in practice settings.

Post hoc analyses of clinical trials data have suggested no increased risk of acute liver injury with saxagliptin.[@R25] We observed no association between saxagliptin initiation and hospitalization with ALF. Notably, across the four data sources, we observed no ALF events among saxagliptin initiators and only one event among comparator OAD initiators.

Consistent with prior clinical trials,[@R26] this study demonstrated no association between saxagliptin initiation and hospitalization for AKI, confirming the renal safety of saxagliptin in real-world settings.

Our finding of no association between saxagliptin initiation and infection is consistent with the overall low incidence rates and risk of infection among DPP-4 inhibitors observed in clinical trials.[@R25] A pooled analysis of 20 randomized trials of saxagliptin, prescribed as a monotherapy or add-on therapy, found similar incidence rates of infection between saxagliptin users (24.2 per 100 patient-years) and the control groups (21.7 per 100 patient-years).[@R25] A meta-analysis of 30 randomized trials comparing vildagliptin with placebo also found no increased risk of infections.[@R28] However, one meta-analysis of randomized trials of DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin) observed an increased risk of nasopharyngitis (risk ratio 1.2, 95% CI 1.0 to 1.4) and urinary tract infections (risk ratio 1.5, 95% CI 1.0 to 2.2) associated with DPP-4 inhibitor use.[@R29]

Our findings demonstrating no increased risk of hospitalizations for severe hypersensitivity reactions among saxagliptin initiators are in contrast with prior clinical trials analyses.[@R25] In one pooled analysis, urticaria and facial edema occurred more commonly among patients with type 2 diabetes mellitus who initiated saxagliptin compared with those receiving placebo (incidence 1.5% vs 0.4%).[@R30] A separate analysis of 20 clinical trials comparing hypersensitivity reactions between users of saxagliptin and comparator drugs or placebo found that rates of these events were more common among saxagliptin initiators (incidence rate ratio 1.67, 95% CI, 1.01 to 2.87); however, incidence rates for both groups were low (saxagliptin, 1.3 per 100 person-years; control, 0.8 per 100 person-years).[@R25] Differences in the definitions of hypersensitivity events between those studies and ours likely accounts for these disparate findings.

Our study has several potential limitations. There is the possibility for unmeasured confounding since not all clinically important variables are consistently captured across these data sources. However, we performed sensitivity analyses to determine the effect of unmeasured variables on measures of effect within each data source and observed that the results were insensitive to unmeasured confounding. Misclassification of both the exposure and outcome is possible. Misclassification of new initiators of saxagliptin or comparator OADs could exist if providers supplied samples or drug rebate cards for varying durations to patients, with no record in the data sources. Moreover, misclassification of new initiators may occur in the UK data sources if the patient was initially prescribed the OAD by a specialist as the general practitioner may not have a record of this initial prescription. Finally, some analyses were based on coding algorithms with \<80% PPV or with very few events, limiting our assessment of risk for these end points. However, very few events in a population exceeding 1.0 million indicate that any risk must be very small.

Our analyses have a number of strengths. Using four data sources, rather than a single database, provided a larger sample for safety analyses and allowed inclusion of patients across a variety of settings, within both the USA and UK, and from private and public health insurance plans, enhancing generalizability. We controlled for numerous potential confounding variables using propensity scores. We used standardized definitions for end points and evaluated the validity of diagnostic coding algorithms for these events using medical records. Finally, the 95% CIs surrounding the relative hazards were generally very narrow, indicating a high level of power. Although we cannot completely rule out associations with the outcomes, we can eliminate the likelihood of moderate-to-large associations.

In conclusion, saxagliptin initiation was not associated with increased rates of hospitalized MACE, ALF, AKI, infections, or severe hypersensitivity reactions. The low risk of these events among saxagliptin initiators, particularly in such large study populations, provides real-world evidence of the safety of this medication.
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